FiercePharma |
Sanofi's eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat
FiercePharma But so far, the numbers on Sanofi's new eczema med look even better, according to Bill Sibold, EVP at Sanofi Genzyme. “Prescriptions are trending ahead of other recent biologic launches in dermatology, including Cosentyx,” Sibold said during the … Sanofi raises outlook but key eczema drug disappoints investors France's Sanofi Raises Earnings Forecast, Pleased With Eczema Drug Uptake Sanofi raises outlook but key eczema drug disappoints investors |
Tag Archives: earnings
France’s Sanofi Raises Earnings Forecast, Pleased With Eczema … – New York Times
Nasdaq |
France's Sanofi Raises Earnings Forecast, Pleased With Eczema …
New York Times France's Sanofi raised its 2017 earnings forecast, citing strong second-quarter growth in consumer healthcare, vaccines and its Genzyme unit and said it was … France's Sanofi raises earnings forecast, pleased with eczema drug uptake Solid start for Dupixent as Sanofi raises 2017 outlook |
Study associates adolescent acne with higher grades, possible future earnings
Adolescents who have acne may have higher grade point averages and higher earning potential in the job market, according to findings from a recent study.
Dermatology Times – Dermatology